Recent EVAX News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/13/2024 02:00:31 PM
- Evaxion receives and appeals delisting determination from Nasdaq, remains committed to Nasdaq listing • GlobeNewswire Inc. • 11/13/2024 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/13/2024 12:30:07 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/13/2024 12:04:38 PM
- Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1 • GlobeNewswire Inc. • 11/12/2024 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/31/2024 02:20:47 PM
- Evaxion announces business update and third quarter 2024 financial results • GlobeNewswire Inc. • 10/31/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/28/2024 01:10:59 PM
- Evaxion to announce business update and third quarter 2024 financial results on October 31 • GlobeNewswire Inc. • 10/28/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/09/2024 03:00:07 PM
- Strong validation of Evaxion’s AI-Immunology™ platform in multiple clinical trials • GlobeNewswire Inc. • 10/09/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/04/2024 11:00:13 AM
- Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform • GlobeNewswire Inc. • 10/03/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/03/2024 11:00:19 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/01/2024 08:30:35 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/26/2024 12:00:05 PM
- Evaxion significantly expands vaccine development collaboration with MSD • GlobeNewswire Inc. • 09/26/2024 11:30:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/20/2024 08:30:25 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/19/2024 12:30:06 PM
- Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction • GlobeNewswire Inc. • 09/19/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/16/2024 11:30:06 AM
- Evaxion reports convincing one-year data from phase 2 trial on AI-designed personalized cancer vaccine EVX-01 • GlobeNewswire Inc. • 09/16/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/09/2024 12:24:01 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/09/2024 12:22:02 PM
- Evaxion reports 69% Overall Response Rate in its phase 2 trial on lead cancer vaccine candidate EVX-01 • GlobeNewswire Inc. • 09/09/2024 12:00:00 PM
One World Products Sets New Standards in Sustainability With Strategic Hemp Innovations • OWPC • Nov 18, 2024 7:54 AM
Kona Gold Beverage, Inc. Updates Multi-Million Dollar Merger and Posts Over $1.2 Million in Q3 Revenues • KGKG • Nov 15, 2024 10:36 AM
HealthLynked Corp. Announces Third Quarter and Year-to-Date 2024 Results with Strategic Restructuring, Third-Party Debt Repayment, and Core Technology Focus • HLYK • Nov 15, 2024 8:00 AM
Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023 • ACGX • Nov 14, 2024 8:30 AM
Unitronix Corp. Publishes Its Cryptocurrency Portfolio Strategy • UTRX • Nov 14, 2024 8:05 AM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM